Interferon Less Effective Against Hepatitis C For African Americans

November 10, 1998

Promising New Liver Cancer Screening Program for Native Alaskans Could Be Effective in Developing Countries

CHICAGO, November 10 - At the American Association for the Study of Liver Diseases 1998 Annual Meeting inChicago, November 6 - 10, researchers discussed disturbing new findings indicating that interferon, the most commonly used drug against chronic Hepatitis C, is much less effective for African Americans than it is for other racial and ethnic groups.

Jay Hoofnagle, MD, of the National Institutes of Health, discussed a study of the role race and ethnicity play in determining how well patients respond to using interferon to treat chronic Hepatitis C. A large, randomized, North American controlled trial of response to interferon compared African American, Caucasian, Hispanic, and Asian patients who were similar in age and in their levels of Hepatitis C virus (HCV) as measured by an antibody called HCV RNA.

At the end of the interferon therapy, only 5% of African-Americans became HCV RNA negative, as opposed to 33% of Causasians, 28% of Hispanics, and 40% of Asians. "The differences in response to interferon in HCV is as yet unexplained," according to the abstract of the research findings presented at the AASLD meeting, "but have major implications for future directions in the therapy of the disease.

For another ethnic minority, Native Alaskans, the AASLD Annual Meeting had some positive news. Brian J.McMahon, MD, of the Alaska Native Medical Center in Anchorage, AK, reported on a screening program that is helping to detect liver cancer and improve survival rates. In late 1982, the Alaska Native Medical Center launched a state-wide program to conduct regular blood tests of all Alaska Natives who have chronic Hepatitis B. Persons with chronic Hepatitis B are at a high risk of developing liver cancer during their lifetimes. The tests evaluated the level of alpha-fetoprotein (AFP) in blood, which is an indicator of liver cancer. Those with elevated AFP were checked for tumors with ultrasound and treated when necessary. The five and ten year survival rate for those found to have Hepatitis C, were 45% and 24% respectively compared to 0% for patients diagnosed with liver cancer prior to the screening program. The program is effective in part because the AFP tests are easy to perform, and the program is relatively cheap to administer and coordinate, a requirement for dealing with the Alaska Native population, which lives in widely dispersed, isolated locations. "In Third World countries and perhaps China, where large numbers of people have been infected with Hepatitis B very early in life, this kind of program could be very effective," says McMahon.
-end-
AASLD is the leading medical organization for liver researchers and physicians. Founded by physicians in 1950, AASLD's mission is to advance the science and practice of hepatology. Today, AASLD provides representation and education for more than 2,200 hepatologists worldwide.



American Association For The Study of Liver Diseases

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.